AI assistant
BIO-TECHNE Corp — Director's Dealing 2022
Aug 9, 2022
30718_dirs_2022-08-09_57a7ad0b-451f-4fe4-aa82-eceb86df7d5f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2022-08-07
Reporting Person: Kummeth Charles R. (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-07 | Common Stock | M | 16918 | — | Acquired | 251960 | Direct |
| 2022-08-07 | Common Stock | F | 11557 | $382.97 | Disposed | 240403 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-07 | Restricted Stock Units | $ | M | 16937 | Disposed | Common Stock (16937) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 100 | Indirect |
| Common Stock | 100 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $106.5900 | 2023-08-18 | Common Stock (256010) | 256010 | Direct |
| Stock Options (Right to Buy) | $125.0500 | 2024-08-09 | Common Stock (194771) | 194771 | Direct |
| Stock Options (Right to Buy) | $177.3200 | 2025-08-08 | Common Stock (90334) | 90334 | Direct |
| Stock Options (Right to Buy) | $177.3200 | 2025-08-08 | Common Stock (60222) | 60222 | Direct |
| Stock Options (Right to Buy) | $190.4100 | 2026-08-07 | Common Stock (85725) | 85725 | Direct |
| Stock Options (Right to Buy) | $190.4100 | 2026-08-07 | Common Stock (57150) | 57150 | Direct |
| Restricted Stock Units | $ | Common Stock (12879) | 12879 | Direct | |
| Stock Options (Right to Buy) | $267.8700 | 2027-08-05 | Common Stock (57442) | 57442 | Direct |
| Stock Options (Right to Buy) | $267.8700 | 2027-08-05 | Common Stock (38295) | 38295 | Direct |
| Stock Options (Right to Buy) | $267.8700 | 2027-08-05 | Common Stock (16650) | 16650 | Direct |
| Stock Options (Right to Buy) | $267.8700 | 2027-08-05 | Common Stock (16650) | 16650 | Direct |
| Restricted Stock Units | $ | Common Stock (8016) | 8016 | Direct | |
| Stock Options (Right to Buy) | $481.8200 | 2028-08-06 | Common Stock (31315) | 31315 | Direct |
| Stock Options (Right to Buy) | $481.8200 | 2028-08-06 | Common Stock (20876) | 20876 | Direct |
Footnotes
F1: Includes (i) 2,862 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 3,562 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on each of August 6, 2023 and August 6, 2024.
F2: Fully exercisable.
F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F4: On 8/7/2022, the Board of Directors certified vesting of 16,937 performance RSUs.
F5: Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.
F6: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7: Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
F8: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F9: Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.
F10: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F11: Options to purchase 5,219 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.